Who owns DECHRA PHARMACEUTICALS?

DECHRA PHARMACEUTICALS has been 100% owned by EQT PARTNERS and ADIA since July 2023.

At what enterprise value was DECHRA PHARMACEUTICALS acquired in 2023?

During the acquisition of DECHRA PHARMACEUTICALS by EQT PARTNERS / ADIA in 2023, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b GBP.

What was the EV/EBITDA of DECHRA PHARMACEUTICALS when it was acquired by EQT PARTNERS / ADIA?

The estimated EV/EBITDA multiple for DECHRA PHARMACEUTICALS is in the range of Above 20x.

When was DECHRA PHARMACEUTICALS acquired by EQT PARTNERS / ADIA?

DECHRA PHARMACEUTICALS was acquired by EQT PARTNERS / ADIA in 2023.

What was the revenue of DECHRA PHARMACEUTICALS at the time of the deal?

The revenue of DECHRA PHARMACEUTICALS at the time of the deal is estimated to be in the range of 450M - 900M GBP.

What was the EBITDA of DECHRA PHARMACEUTICALS during the acquisition?

DECHRA PHARMACEUTICALS's EBITDA is estimated to be in the range of 100M - 200M GBP.

How is the data for the DECHRA PHARMACEUTICALS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DECHRA PHARMACEUTICALS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.reuters.com/business/healthcare-pharmaceuticals/eqt-take-uks-dechra-pharma-private-about-6-bln-deal-2023-06-02/#:~:text=June%202%20(Reuters)%20%2D%20Swedish,veterinary%20drugmaker%20said%20on%20Friday.

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaDECHRA PHARMACEUTICALS

07/2023

DECHRA PHARMACEUTICALS acquired by EQT PARTNERS & ADIA

UNITED KINGDOM Life Sciences / Pharma & Biotech EV 3b - 100b GBP

Context

EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price. EQT intends to accelerate investment in the company's innovation pipeline and support further international acquisitions without the pressure of quarterly earnings reporting.

DECHRA PHARMACEUTICALS, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Northwich, UK, Dechra is a global specialist in veterinary pharmaceuticals. Unlike animal health giants that focus on livestock vaccines, Dechra carved out a high-margin niche in "specialist" treatments for companion animals (dogs, cats, horses). It is a world leader in veterinary endocrinology (treating diseases like Cushing's in dogs) and topical dermatology.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2023	OAKLEY CAPITAL INVESTMENTS	LIBERTY DENTAL GROUP	GERMANY	Implants & Prosthetics
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Medical Devices
07/2023	ELOS MEDTECH	KLINGEL MEDICAL GROUP	GERMANY	Implants & Prosthetics
06/2023	NOVO NORDISK	BIOCORP	FRANCE	Medical Devices
04/2023	HALMA	APRIOMED	SWEDEN	Medical Devices
04/2023	Innovad Group	Herbonis	SWITZERLAND	Animal Health
04/2023	SARTORIUS	POLYPLUS	FRANCE	R&D Biotech
02/2023	ARDIAN	THERADIAL	FRANCE	Medical Devices
01/2023	Dermapharm	Arkopharma	FRANCE	Nutrition & Dietary Supplements

REFERENCES

Valuation range: EV 3b - 100b GBP

Revenue range: 450M - 900M GBP

EBITDA range: 100M - 200M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DECHRA PHARMACEUTICALS by EQT PARTNERS / ADIA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: dechra pharmaceuticals

Acquirer: eqt partners / adia